UK | PREADViSE

About The Study

The PREvention of Alzheimer's Disease with Vitamin E and SElenium (PREADViSE) study is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

The purpose of PREADViSE is to determine if taking antioxidants, like selenium and/or vitamin E supplements, can prevent Alzheimer's disease and other less common forms of dementia.

PREADViSE is sponsored by the National Institute on Aging of the National Institutes of Health, a government agency. This study is coordinated by researchers at the University of Kentucky Sanders-Brown Center on Aging, an Alzheimer's Disease Center. More than 7500 of the more than 35,000 men in SELECT elected to take part in PREADViSE. PREADViSE and SELECT are now transitioning to Centralized Follow-up, and each PREADVISE participant will have an opportunity to continue his participation in both studies. However, you must first participate in SELECT Centralized Follow-up to take part in PREADViSE Centralized Follow-up.

The Selenium and Vitamin E Cancer Prevention Trial is a very important research study taking place in the United States, Puerto Rico, and Canada. SELECT was trying to find out if taking selenium and/or vitamin E supplements can prevent prostate cancer. Data from the SELECT trial have now shown that the supplements offered no benefit in the prevention of prostate cancer. However, there are other health questions that SELECT hopes to answer with your continued participation.

SELECT is sponsored by the U.S. National Cancer Institute, a government agency. The study was coordinated by a group of researchers known as the Southwest Oncology Group. More than 35,000 men made the decision to take part in SELECT. The Centralized Follow-up phase of the SELECT trial is being coordinated by the SELECT Data Center in Seattle.